La CHAIRE EN GESTION DES BIO-INDUSTRIES a pour mission de développer les connaissances scientifiques et stratégiques sur la gestion des entreprises et sur la dynamique des grappes d'activités industrielles des bioindustries.
INTRODUCTION
This article analyzes the perceptions of company executives on the financing-related issues and difficulties facing Canadian biotechnology companies. The analysis is based on in-depth interviews with 43 companies in March and April 2000. We document the perceptions of the interviewees for various dimensions that are relevant to biotechnology financing. The methodology used identifies the financing issues and difficulties by stage of product and company development for the biopharmaceutical, agbiotech, and bioenvironmental segments of the biotechnology industry.
The objective of this study is to prepare for the next phase of a systematic analysis of the adequacy of the match between the supply and demand of capital for the Canadian biotechnology industry. The sample studied consists of 32 companies located in the Montreal cluster and 11 companies situated in Ottawa, Toronto, Saskatoon, and Vancouver. The purpose of the study is to determine the structural configuration of the financing issues discussed, and not to statistically validate the importance of these issues for the population of Canadian biotechnology companies. The approach used is similar to that used in analyzing cases (i.e., analyzing a sufficient number of cases until no new significant dimensions emerge). For this purpose, we use an interview discussion guide based on the commercialization and development stages in Jolly (1997) . This facilitates interview analysis, and the construction of profiles for the financing-related issues and difficulties encountered by a typical biotechnology firm. The interview guide, which is found in Appendix B, allows interviewees to discuss relevant dimensions that are not explicitly dealt with in the guide.
The remainder of the article is organized as follows. The next section presents the objectives of the study. Sections III and IV describe the sample and the methodology used, respectively. Section V presents a synthesis and analysis of financing-related issues and difficulties based on comments elicited from the interviewees. We discuss which concerns are important, and what concerns should be analyzed in more depth in subsequent studies to better understand the financing-related issues and their relevance. Finally, Section VI presents our conclusions as well as suggested areas for further study.
OBJECTIVES OF THE STUDY
The objectives of the new Canadian Biotechnology Strategy announced in August 1998 are to create a better investment climate and to encourage the development, application, and export of biotechnology products and services. The sixth report of the National Consultative Committee on Biotechnology (Leading in the Next Millennium), which has had a direct impact on the renewal of the Canadian strategy, highlights that achieving targeted objectives must be accompanied by measures facilitating access to capital. According to the Committee, if the industry is to succeed in increasing its annual revenues fivefold (from $1.1 to $5 billion) and in tripling the number of jobs (from 11,000 to 30,000) 1 , then companies need access to a steady flow of capital to move products beyond the initial development stage. In turn, this would greatly benefit the Canadian economy.
Biotechnology industry players are unanimous that their research-focused industry must do a strategic about-face and focus on commercializing products. Therefore, facilitating access to capital is a priority. Many existing companies are entering or will soon enter the development and commercialization stages, where financing is particularly critical. Paradoxically, little information is available on stage-related financing issues and difficulties. Specific questions that need to be answered include: How do successful commercialization attempts differ from failures? What types of financing problems are encountered? What are the potentially significant concerns of typical firms in the various segments of biotechnology activity?
The main objective of this study is to identify, document, and analyze financing-related issues and difficulties for the three main segments of activity (biopharmaceutical, ag-biotech, and bioenvironmental) at the various stages up to market entry. We begin with a thorough exploratory study to identify financing-related issues and difficulties. This facilitates the selection of which issues to concentrate on in subsequent quantitative research. Our approach involves characterizing the viewpoints of company executives (demand). Soliciting the viewpoints of suppliers of capital (supply) should be the focus of a subsequent study. The detailed analysis of the perceptions of the interviewed company executives provides the raw data upon which we evaluate the measures that could be implemented to improve access by Canadian biotechnology firms to capital.
A more in-depth knowledge of biotechnology financing-related issues and problems is important for many reasons. Small and medium-size enterprises (SMEs) represent a large proportion of the Canadian biotechnology firms in number. Many of them have already entered, or are in the process of entering, the pre-clinical and/or commercialization stages in which capital requirements are larger. Furthermore, the number of products in the product pipeline is growing rapidly. It is reasonable to assume that the aggregate capital requirements of Canadian biotechnology companies will increase significantly. Although financing is considered a key development dimension, there is relatively little information available on how much capital is required, and on the difficulties encountered by companies when seeking financing. Inadequate capitalization affects the competitiveness of Canadian biotechnology companies and makes them potential acquisition targets. Strengthening competitiveness also is a major issue given the significant economic advantages associated with production and commercialization. Therefore, a better understanding of the financing issues and concerns faced by Canadian biotechnology companies is a pre-requisite for evaluating whether Canadian financial markets can provide sufficient access to capital, and for implementing policies to encourage the development stages with the greatest profit potential to be undertaken in Canada.
METHODOLOGY

Description of the Sample
The sample for each segment studied herein is presented below. In total, 43 of the potential sample of 51 firms were interviewed. 
Interviews and analysis
Company commercialization process and development stages
The study first discusses financing-related issues and difficulties using a case analysis approach for a representative sample of companies for each of the three chosen segments of biotechnology activity, namely: biopharmaceutical, ag-biotech, and bioenvironmental. Semi-structured interviews using a prevalidated interview guide with the executives of the sample companies are conducted to identify the issues and difficulties with past, present, and potential financings at various stages of the commercialization process. We draw upon the overall working experience of the interviewees, and not just upon their own experience. We use Jolly's (1997) 2 classification of the commercialization process (see Appendix A). This classification of the value creation process includes five sub-processes that are similar to the conventional stages of technological innovation. These sub-processes are: 1) imagining, 2) incubating, 3) demonstrating, 4) promoting, and 5) sustaining. Jolly (1997) argues that these five sub-processes of technological innovation correspond quite well to the main categories of sources of funds and financing methods used by technology-based firms. Therefore, it is relevant to use this approach as a backdrop for analyzing the evolution of financial requirements in the various sectors of the biotechnology sector, and for building a typical profile by sub-process and/or stage of commercialization.
Our case analysis procedure consists of the following stages: 1) Conduct an in-depth literature review of biotechnology financing issues.
2) Design a semi-structured interview guide of financing-related issues that is superimposed over each of the sub-processes of the Jolly model (1997) , and is pre-validated with several target firms. 3) Select representative sample companies in each of the three segments of the biotechnology industry. 4) Conduct the field interviews. 5) Conduct in-depth analysis of the interview content. 6) Construct the typical profiles.
Relevant dimensions of the analysis and discussion guide used
Six main dimensions, which were retained following the literature review, are systematically explored in the interviews. The main dimensions used include:
-Types of projects -Differences in perception of risk and return -Degree of founder commitment and financial participation in the project pipeline -Disclosure of information -Relevance and use of strategic alliances as a source of financing -Government commitments and/or guarantees for managing risk -Other dimensions
SYNTHESIS AND ANALYSIS OF FINANCING-RELATED ISSUES AND DIFFICULTIES
This section is divided in two sub-sections. The first sub-section identifies the main financing-related issues and difficulties addressed by the interviewees for each of the product development stages. The profiles contain representative summaries of the perceptions of the interviewees as identified by the detailed content analysis of the interviews. Our objective is to provide a concise description of the financing-related issues and difficulties, and not to evaluate their veracity. A table of quotes completes this section of the study. It provides some selected and representative illustrations of the perceptions of the interviewees. The second sub-section presents a systematic analysis of the financing-related issues and difficulties, and discusses further avenues to assess veracity and potential solutions.
Synthesis of main financing-related issues and difficulties
Biopharmaceutical Segment
The overall availability of capital in Canada at the pre-start-up and start-up stages for this segment does not appear to be a major issue. According to the interviewees, few opportunities are lost during these stages, and existing financing institutions appear to offer real support to emerging companies. The problems appear to be linked to:
#"the structure of the supply of capital, which is perceived as not being competitive enough and as being too institutionalized at these stages; #"the overly conservative attitude toward risk of Canadian investors, especially compared to their U.S. counterparts; and #"on the effect of these two problems on:
-the way in which available capital is provided (excessive syndication), -initial capitalization provided by fund suppliers is perceived to be insufficient and suboptimal for companies during these stages, and -company and technology valuations are too low versus valuations for comparable U.S.
companies.
Other associated difficulties on which interviewees agree include: #"delays encountered in obtaining first financings are too long, as is the due diligence process; #"excessive red tape resulting from the different criteria used by the three main sources of capital that are more or less linked to government support; #"excessive amount of time by executives on seeking financing; and #"lack of experience of venture capitalists in valuing biotechnology companies.
The existence of a large number of structures and institutions with different criteria for valuing essentially the same projects is the basis for the above difficulties. The three main sources of capital at the pre-startup and start-up phases are venture capitalists, research and export grants, and tax credits. While all three are linked in varying degrees to the government, each apparently has different administrative criteria.
Another underlying difficulty is probably differences in the source of Canadian and U.S. venture capital. In Canada, approximately 60% of such capital comes from government or labour-sponsored funds, compared to only 1% in the U.S. Other issues, such as taxation, that can affect financing of product development in the early stages, are discussed below.
Determining value and project risk for products in the early stages is undoubtedly one of the underlying causes for the above difficulties. At least two approaches exist for confronting these inherent difficulties. The first approach is to develop and establish policies and strategies to allow players to better diversify their risk. It is normal for investors faced with excessive uncertainty to try to reduce risk by investing in a greater number of projects, or to share the risk with others in order to decrease each project's share of the investor's investment budget. However, for the user of funds, these diversification measures by the suppliers of funds has the effect of increasing the number of players involved, and potentially of lowering the aggregate amount of funding procured. In other words, many small investments in many companies make the burden of seeking financing for biotechnology firms proportionally heavier.
A second potential approach is to better delineate the various biotechnology segments so as to limit the difficulties caused by estimating risk and value. The interviewees state that risk, financing needs, and valuations vary by segment. A better delineation of segment-specific characteristics potentially can improve risk management and hedging policies, and, thus, limit valuation difficulties. However, this is likely to require much higher product-specific knowledge within the personnel of the fund suppliers.
Grouping of projects or companies has a similar effect in that it tends to broaden the portfolio of opportunities or the product pipelines by creating larger companies. However, this is a method that can lead to a number of other issues that are not limited to financing.
Competition from other sector users of venture capital (particularly other high-technology sectors) is another major underlying issue for the difficulties experienced in the financing of biotechnology companies, especially at the early stages. Investments must generate returns equivalent to those of other sectors for similar levels of perceived risk. Therefore, the first concern is to ensure that biotechnology companies can provide investors with equivalent risk-adjusted returns. Otherwise, measures to ensure adequate financing will be effective, at best, only over the short-run. Although the preceding statements may at first appear obvious, we have no hard evidence about the effects of competition from other sectors on biotechnology financing in Canada, nor about the relative effectiveness of government policies across industrial sectors. This is the case even though these factors are likely to directly affect the overall amount of available biotechnology risk capital.
Ag-biotech Segment
The main financing-related issues and problems perceived by the interviewees from the ag-biotech companies are very similar to those from the biopharmaceutical segment. The following paragraphs summarize the problems according to the stages of commercialization in the Jolly model.
The majority of the interviewees believe that pre-start-up capital is available and granted within reasonable delays and acceptable levels of red tape. University scientists appear to be quite knowledgeable about applying for grants, and think that university support is adequate.
Start-ups require much larger amounts of capital, and this seems to be a problem for the majority of companies interviewed. They perceive this stage as being not well-understood by (mainly venture capitalist) investors. Interviewees also believe that venture capitalists are too conservative with respect to risk. By advancing insufficient funds, venture capitalists increase the number of meetings and delays. This eventually affects the competitiveness of this sub-segment of the Canadian market compared to the situation in the U.S.
Since the number of companies in this segment is constantly increasing, the scattering of funds by venture capitalists among an increasing number of companies is perceived by the interviewees as being "to no one's advantage". Some interviewees believe that mergers and acquisitions in this segment should be encouraged in order to strengthen the companies technologically and to increase their financial assets de facto. Strategic alliances, particularly for distribution, also are considered essential. Interviewees see themselves as having no choice in the matter if they want to be competitive with the large multinationals that dominate the segment. Many companies in this segment also perceive loan syndication by venture capitalists as an irritant.
Subtle competition for financing by firms in the biopharmaceutical segment is also considered a major difficulty by ag-biotech executives. The interviewees believe that this segment is not a favoured investment for Canadian investors.
Many companies also find that product approval delays and the associated costs are excessive. Regulations are not only heavy, but also sometimes redundant. The interviewees believe that rationalisation of the approval process is required to enhance segment competitiveness.
Interviewees are unanimous about the major difficulties in financing scale-up and commercialization. They would like to have access to larger amounts of financings in order to compete against the multinationals.
Interviewees claim to have difficulties in attracting or even holding on to the best human resources because both salaries and taxes are not competitive with those in the U.S. Interviewees believe that employment-related tax deductions are a step in the right direction, but that they are insufficient to retain the best candidates after the five year exemption period. They believe that government should be more aggressive in creating a more hospitable environment in Quebec for an industrial segment that is still in its infancy.
Few of the companies interviewed are at the promoting stage (production and marketing), and none of those at this stage mention lack of capital as being a difficulty. This implies that the main financing difficulties are observed in stages two and three of the commercialization process. Problems mentioned are typical for any company wanting to position itself as a world-scale player. They acknowledge that strategic alliances are still the most common strategy for sharing risk and funding products. This requires that the participants have an understanding of "different cultures' food habits", and of the value added by partners through after-sales support and service. Interviewees also believe that strategic alliances enhance their credibility to fund providers.
Those companies who are or soon will be at the sustaining stage think that the challenges are managerial and not financial. Since environmental scanning needs to be used to not only satisfy clients' needs but to predict and surpass them, they believe that the current system of R&D tax credits needs to be maintained and broadened.
Bioenvironmental Segment
The number of companies in the bioenvironmental segment is quite small. This reflects the proportion of such companies compared to the biopharmaceutical or ag-biotech segment, particularly in the Montreal cluster. Therefore, it is not possible to construct a representative picture of financing-related issues and difficulties for this segment. The following text summarizes the interviewees' comments.
The two bioenvironmental companies interviewed did not apply to venture capitalists for funds. Instead, they used founders' capital at first, then self-financing. These companies are not primarily in the bioenvironmental area. Outside financing, particularly bank financing, is common for these firms. Executives interviewed note the importance of having a good relationship with one's banker, whom they consider to be a partner, and not just a provider of funds. Disclosing information is not a problem, nor is local competition since competition is mostly from abroad.
Strategic alliances are the fourth-largest source of financing for these firms, and are of critical importance. The companies interviewed in this segment are mostly in chemicals and energy, particularly oil. They have formed solid alliances with oil companies and finance part of their bioenvironmental activities from these sources of funds.
A fifth source of financing is government environmental programs and partnerships with the government.
The various sources of financing are insufficient according to the interviewees, and companies in this segment try to avoid large capital-intensive projects. Segment profitability depends on environmental regulations. Government priorities enhance a project's appeal and facilitate its financing. Interviewees believe that capital availability and growth opportunities in this segment are largely dependent on anticipated government actions regarding the negative externalities of industrial activity on the ecosystem. Consequently, financing of "green" projects in terms of accessibility, quantity, and cost is considered more volatile (risky) than other biotechnology projects, all other things being equal.
Interviewees believe that government guarantees are interesting and relevant, but insufficient. They perceive that the challenge is to improve the environmental consciousness to give green investments value. If expenses to eliminate negative externalities could be seen as being indispensable, such projects could generate economies of scale and return on investment while making environmental legislation more effective.
Table 2 -Quotes of interviewed CEOs
1. "There are many places to go where we can apply for a lot of money, but we waste most of our time satisfying administrative criteria to in the end get money that all comes more or less from the same place. The same specialized funds, each with their own control and verification teams, all tend to start with a 'series of small false investments' rather than the real venture capital financing that some entrepreneurs are looking for." 2. US investors: "When they invest in a company, they are 100% committed. They put in X million dollars and leave the company free to create value and do what it has to do." In Canada: "We'll invest X million dollars and give you 20% today, 20% in six months. This is a typical Canadian attitude!" 3. "We are always facing the same players, and if one of them determines a value, no one will go higher."
"Venture capitalists lack competition in Canada and are willing to invest too small amount of money. But still, it almost seems like they invest in groups."
4. "We are constantly in the middle of financing. We finish a round for $10 to $12 million, which allows us to survive for 9 to 10 months, and then it takes another 10 to 12 months to do another one."
5. "You have a hard time to get substantial private financing. You are not necessarily ready to go to the IPO market, which is not really developed in Canada also."
6. "Some companies have raised $29 million over the past four years. In the U.S., $29 million is considered start-up cash. At the same stage of development, U.S. companies all have US $70 to $100 million in the bank."
7. The same technology, expertise, progress… "You change your address and you double your valuation!"
8. "So regardless of how a scientist perceives what the values were, the truth is that the venture capitalist wants return equivalent to other sectors he could invest the money in."
"If too much money is given too quickly, it won't be used properly. People got lazy. They didn't believe that they had to be accountable to the investors."
"If you go all hog-wild, spending all your money on advancing your science very aggressively, and things go wrong and you're not able to find capital, then you're screwed. But if you don't spend enough money on your science, and control your burn rate, and your investors are looking for data, then you're screwed too. Hard choices."
"Even if all companies that started off had $20 million, it's not obvious that they would find all the human resources that they need."
9. "The model for most Canadian companies is to align themselves with a strategic partner. But that's a problem in itself, ….Two years of cash with no revenue coming in, so you're not in a strong position to bargain with anybody."
"If development is done with a foreign partner, development and manufacturing will not be done here but abroad."
"We were very good at pulling fish out of the sea, and trees out of the forest…it always went somewhere else. We run the risk of repeating the same problem in Canada with our biotechnology properties."
"In agricultural biotechnology smaller companies have fewer customers which impacts the valuation of their technology…just getting to the distribution channel, especially with patents, because…Monsanto has the dominant patent for that, so smaller medium-size companies that do not have access to that have to rely on big multinationals."
"Mergers and alliances are the way to go. It's important, even with the multinationals, they'll put your product through the regulatory environment and get it to market, so you can actually make money, so there's advantages to that."
10. "Government has done quite a good job. Americans, for example, are very impressed with the level of research and development investment tax credits that are available to Canadian companies for doing R&D. Similarly, Industry Canada has done a good job, finally, and it's only finally, with their Technology Partnerships Canada program (TPC)."
"Government can play a very strong role in developing industry …if they want to develop it here, with all the hurdles that are in Canada for developing high-tech industries, they should be looking at some sort of granting procedures, not just for scientific development, like NSERC."
Analysis of Main Financing-related Issues and Difficulties
One of the primary functions of financial markets is to efficiently allocate funds obtained from savers to users and uses of funds. Thus, each financing transaction involves the following two parties: the supplier of funds and the user of funds. Financing transactions generally are only consummated when these two parties hold similar expectations about the future risk-adjusted prospects of projects.
A market is deemed to be allocationally efficient if funds flow to those projects with the highest expected (or promised) risk-adjusted returns. The project funded at the margin is the one with a risk-adjusted expected return equal to the risk-adjusted cost of funds. The allocational efficiency of a market is generally measured ex post, that is, using risk-adjusted realized returns. The allocational efficiency is the same across industry sectors and/or national boundaries if markets are integrated. If barriers to investment exist, markets are referred to as being segmented, and allocational efficiency may differ systematically across industry sectors and/or national boundaries.
In the preceding section of this report, we presented the financial difficulties and perceptions of users of funds in the biotechnology sector of the Canadian economy. While it is tempting to draw conclusions and formulate public policy implications based on these knowledgeable perceptions, prudence suggests otherwise. The reason is that this information is incomplete because it does not include the observations and perceptions of the other party to each financing transaction, namely, the suppliers of funds. Furthermore, these observations and perceptions may not be perfectly aligned with reality. Thus, the findings summarized in the preceding section of this report lead to a series of unresolved concerns that require further thought, information gathering and analysis before more definite conclusions can be reached about the difficulties and problems that exist in financing the Canadian biotechnology sector.
The first concern is whether or not an equity gap exists in Canada for firms in the biotechnology sector for one or more product phases, and whether or not any identified equity gap differs for this sector versus other industrial sectors of the Canadian economy. The interviewees perceive that too many projects with risk-adjusted expected returns that exceed the risk-adjusted cost of capital either are not financed and/or have excess difficulties in being financed. If these perceptions are true, this suggests that suppliers of funds systematically underestimate the future return prospects of projects and/or overestimate the riskiness of projects in this industrial sector of the Canadian economy. However, another possibility is that the perceptions of the interviewees contain bias because entrepreneurs and managers in the biotechnology sector systematically overestimate the future return prospects of projects and/or underestimate the riskiness of projects in the biotechnology sector. The literature documents systematic over-optimism on the part of project sponsors but no study has yet addressed the situation of projects in the biotechnology sector.
This concern can be addressed by comparing the realized risk-adjusted returns on projects funded in this industrial sector with initial projections by their sponsors, by documenting the adherence of actual activities to those promised by the project sponsors, and by examining the equally and dollar-weighted "mortality" history of projects in this industrial sector. This concern also can be addressed by comparing the realized risk-adjusted returns on firms funded in this industry with those in other industrial sectors of the Canadian economy (particularly high technology).
A second concern is whether or not suppliers of funds in Canada have substantially different risk tolerances than suppliers in other countries, particularly, in the United States. Systematic differences in risk tolerances across national markets are important if capital markets are segmented. In a segmented market, the risk premia required by investors in the market with lower risk tolerance exceeds that required by investors in the market with the higher risk tolerance. In turn, the higher risk tolerant market would place a higher valuation than the lower risk tolerant market on firms with the same risk and return prospects. The interviewees perceive higher valuations in the U.S. compared to the Canadian market for the same firm. Thus, they conclude that U.S. investors are more risk tolerant than Canadian investors. However, this conclusion makes a number of assumptions that need to be verified. First, it assumes that the nondiversifiable risk for investment in the same project is the same across national boundaries. Such will not be the case if U.S. investors are able to achieve a higher level of portfolio diversification due to a wider range of investment opportunities in the U.S. Second, it assumes that the average forecast accuracy of U.S. and Canadian suppliers for the expected returns and/or risk of projects is about the same.
The second concern can be addressed by comparing the realized risk premia for projects and firms in the biotechnology sector between the U.S. and Canada. If the perceptions of the interviewees are accurate, the U.S. risk premia will be systematically lower than those in Canada. The interpretation of the existing empirical evidence on the total market suggests that this prediction will not be supported empirically. An examination of the realized risk premia on the market for periods of 10 to 30 years finds that actual risk premia are significantly higher for the U.S. market. Furthermore, a much higher proportion of biotechnology funding is from public funds in Canada than in the U.S. The risk premia embedded in the cost of funds for public fundings of firm investment is generally extremely small or nil.
A third concern is the risk management procedures used by Canadian suppliers of funds. The interviewees find that each supplier's financing commitment is too small, and that this leads to too many different suppliers of funds (excessive syndication) for each financing. Not surprisingly, as the number of suppliers required to fund the same dollar investment increases, managers of biotechnology firms have to devote greater time to obtain funding. The reason is that many suppliers of funds appear to fulfil their managerial (sometimes fiduciary) duties by conducting their own due diligencies, their own evaluations of project worth, and their own project monitoring. Increases in the number of suppliers to fund the same dollar investment also increase co-ordination and other costs of syndicate management. This suggests a number of questions that require further examination. First, can more of these managerial duties be harmonized or centralized with a lead, especially for government suppliers of funds? For example, can the criteria used to assess project funding worthiness by public venture capital funds, public research granting agencies, and R&D tax credit agencies be harmonized to a greater extent? Second, are there regulatory rules or regulations that hamper the delegation or transfer of such managerial duties to a "lead" fund supplier? Third, how do the risk management practices of Canadian suppliers of funds compare with those in other countries, such as the U.S. and Germany? Fourth, is there a role for a derivative instrument to hedge biotechnology risk, can such risk be quantified, and can such a derivative instrument be designed? A fourth concern is the level of technical knowledge and sophistication of personnel in the providers of capital to the biotechnology sector. The interviewees perceive that a number of decision-makers in the fund supply business are relatively new and inexperienced in terms of biotechnology project assessment. If such is the case, this would suggest that resources need to be devoted to rectify this deficiency. However, we expect that the suppliers of funds would identify a similar concern about the level of financial knowledge and sophistication of personnel in the biotechnology firms. What needs to be examined in more depth here is whether or not fund suppliers are concerned primarily with the value creation aspects of product introduction and development, and whether or not biotechnology firms are concerned primarily with the technical aspects of product introduction and development. In other words, how congruent are the primary concerns of the two major parties to each financing transaction, and does this congruence diverge between financings?
Conclusion
In this study, we presented the financing-related issues and difficulties faced by Canadian biotechnology firms, which were elicited during the in-depth personal interviews with a representative sample of executives from firms in the Canadian biotechnology sector.
This concluding section of this exploratory study on financing-related issues and difficulties of Canadian biotechnology companies consists of three sub-sections. The first sub-section summarizes the financingrelated issues and difficulties identified by executives from the interviewed biotechnology firms. The second sub-section highlights certain issues that directly affect the development potential of this promising segment of the new economy. It deals with the state of our knowledge in this area, and outlines a number of studies that need to be conducted in the near future to further our understanding of the state and performance of the sources of financing available for bio-industry financing in Canada.
Financing-related Issues and Difficulties from the Perspective of Canadian Bio-technology Firms
The major observations drawn from the in-depth personal interviews can be summarized as follows:
#"While the interviewees believe that sufficient capital is available, they state that the cost of this capital is higher in Canadian versus U.S. markets.
#"The interviewees perceive the procurement of capital as being onerous in terms of the conditions of financings and in terms of the management time spent on raising external funds. According to the interviewees, this is caused by fund suppliers being overly risk averse and somewhat inexperienced. This manifests itself in comments by the interviewees that fund suppliers use financing tranches that tend to be excessive in number and too small in dollar value, by excessive financing syndication, and by lengthy and unharmonized due diligence and valuation processes.
#"The interviewees believe that the biotechnology sector, and particularly some sub-segments during the early stages of product development, may face relatively greater barriers to capital markets compared to other industrial sectors.
Deficiencies in our Knowledge About the Financing of Canadian Biotechnology Companies
The interviews conducted across the country highlight the need for a better understanding of the structure, workings, and level of performance of the system and networks used by both users and providers of biotechnology capital in Canada. Many unknowns remain with regard to this supply of capital. Specific issues include: i) whether or not sufficient capital is available to meet the needs of various companies and the technological stages of development in the biotechnology sector; ii) the efficacy and efficiency of the system for financing biotechnology projects and firms; iii) the attitudes toward risk and the risk tolerances of the various providers of capital; and iv) the effective integration of capital from government sources into an overall system of financing that functions well and is optimally harmonized. All of these issues and several related issues need to be analyzed in more depth in the near future, in order to increase our understanding of the factors that increase the efficiency of the supply of capital to the biotechnology sector.
To recapitulate, while this study makes a significant contribution to addressing some of the gaps in the knowledge base required to draw conclusions and formulate public policy for the enhanced development and competitiveness of the biotechnology sector in Canada, much work remains. Avenues for further study include:
#"A study of the main financing-related issues and difficulties based on interviews with Canadian and U.S. suppliers of capital to the biotechnology sector. This study would examine similar issues as were examined in this study.
#"A study to determine how the equity gap (if any) for Canadian firms in the biotechnology sector differs from that for Canadian firms in other industrial sectors. This study would examine issues such as the ex post risk-adjusted returns of Canadian biotechnology firms versus U.S. biotechnology firms, and versus Canadian and U.S. firms in other industrial sectors, and the differences between expectations and realizations for various measures of financial performance for specific product developments for Canadian biotechnology firms.
#"A study to determine if the risk tolerances of Canadian suppliers of funds to the biotechnology sector differ from the risk tolerances of foreign (specifically, U.S.) suppliers of funds to the biotechnology sector. This study would examine issues such as the risk aversion implied by the ex post risk-premiums for Canadian biotechnology firms versus U.S. biotechnology firms, and versus Canadian and U.S. firms in other industrial sectors.
#" A study of the risk management procedures used by Canadian suppliers of funds to the biotechnology sector. This study would address issues such as syndicate size, optimal tranche financing practices, due diligence practices, evaluation methodologies and practices, harmonisation of practices, and the need for and mechanics of derivative instrument design and use for biotechnology risk.
#" A comparative study of the congruence of goals, outlooks, technical knowledge and sophistication of personnel in the fund providing and fund using sides of the biotechnology industry in Canada.
